bioAffinity Technologies (BIAF) H.C. Wainwright 28th Annual Global Investment Conference summary

Conference overview

• Over 500 companies from sectors like life sciences, technology, crypto, metals, mining, and energy participated in the event.

• The event featured presentations from companies focused on innovative diagnostics and early cancer detection.

Market landscape and unmet needs

• Lung cancer remains the leading cause of cancer deaths globally, with over 19 million at-risk Americans and 34 million at-risk individuals in the EU.

• The global lung cancer diagnostic market is projected to reach $38 billion within eight years.

• Early detection dramatically improves survival rates, with over 90% 10-year survival if caught at Stage 1A.

Product innovation and performance

• CyPath Lung is a noninvasive, AI-driven test for early lung cancer detection, reimbursed by Medicare and most private insurers.

• The test shows 92% sensitivity, 87% specificity, and 99% negative predictive value for small pulmonary nodules.

• The technology profiles the lung microenvironment using sputum samples to distinguish cancer presence.